Dominant negative properties are conferred on protein kinase (PK) Cα by mutation of the phosphorylation site in the activation loop of the kinase domain. To address the universality and\or specificity of such mutations, analogous alterations were introduced in other members of the PKC family and tested for their effects on the function of co-transfected activated PKC. For all three subclasses of the PKC family, mutations of the predicted activation loop phosphorylation sites resulted in dominant negative properties. These properties were not restricted to the cognate
INTRODUCTION
Protein kinase (PK) C is a family of serine\threonine protein kinases that are regulated through agonist-induced hydrolysis of membrane phospholipids and are considered to play critical roles in many signal-transduction pathways [1] [2] [3] . This enzyme family comprises eleven members divided into three groups : (i) classical (c)PKC (α, β " , β # -and γ), which are Ca# + -and phorbol-ester\ diacylglycerol (DAG)-dependent ; (ii) novel (n)PKC (ε, δ, η, θ and µ\PKD), which are phorbol-ester-\DAG-dependent but do not require Ca# + ; and atypical (a)PKC (ζ and λ\ι), which do not respond to Ca# + or phorbol ester\DAG, although PKCζ can be activated by phosphatidylinositol 3,4,5-trisphosphate [4] , as can other PKC family members [5] [6] [7] .
Several reports have revealed an additional and highly efficient mode of control of PKC involving its phosphorylation. This may involve both autophosphorylation [8] and transphosphorylation [9, 10] , as well as activation-induced dephosphorylation [11, 12] . Consistently with a critical role in function, PKCα expression in bacteria yields an unphosphorylated precursor that does not require phosphorylation for the formation of a functional enzyme-substrate complex, but does appear to require phosphorylation for catalytic activity [13] . In eukaryotes, pulse-chase experiments demonstrate that PKCα undergoes a series of phosphorylations within the first hour post-synthesis that account for its conversion into an active, albeit effector-dependent, protein kinase [14] .
Cazaubon and colleagues [15, 16] have shown that the phosphorylation of a threonine residue present in the activation loop within the catalytic domain is involved in controlling PKCα activity. Similar observations have been made for PKCβ [17] . In PKCα, the substitution of Thr-497 Ala results in the production of an unphosphorylated and inactive 76 kDa PKCα form. Co-expression in COS-1 cells of an activation loop PKCα mutant and wild-type (wt) PKCβ " leads to the expression of a fast migrating PKCβ " protein that is similar in size to the unphosphorylated primary translation product of PKCα [15] . Thus this Abbreviations used : DAG, diacylglycerol ; FACS, fluorescence-activated cell sorting ; PK, protein kinase ; PKM, catalytic fragment of PKC ; ΨSS, pseudo-substrate site ; TRE, TPA (or PMA) response element ; wt, wild-type. 1 Present address : Synthelabo Recherche (L.E.R.S.), 31 Avenue Paul, Vaillant-Couturier, 92220 Bagneux, France. 2 To whom correspondence should be addressed.
PKC isotypes, but were effective across the different subclasses. For example, two PKCζ mutants (atypical isotype) inhibited both PKCα (classical isotype) and PKCε (novel isotype). For all these mutants, inhibition correlated with an ability to prevent the accumulation of phosphorylated PKCα, consistent with the expected mode of action. In the case of the PKCα mutant, it was shown that inhibition required the full-length mutant protein. The results provide evidence for the involvement of a common step in the phosphorylation of all PKC isotypes.
PKCα mutant appears to have dominant negative properties that can affect PKCβ. Recent studies have suggested that other relevant phosphorylations take place in PKCα. Phosphorylation at Thr-638 at the C-terminus of PKCα controls the duration of activation by regulating the rate of dephosphorylation and, consequently, inactivation of PKCα [18] . The phosphorylation at the equivalent site of PKCβ " (Thr-642) and PKCβ # (Thr-641) may be essential for PKCβ activity [19, 20] , although these proteins may also be hypersensitive to dephosphorylation and inactivation (discussed in [14] ). Further studies on PKCα define the Ser-657 site of phosphorylation as controlling the accumulation of phosphate at other sites on PKC, as well as contributing to the maintenance of the phosphatase-resistant conformation [14] . Sites equivalent to Thr-638 and Ser-657 have been shown to be phosphorylated in baculovirus-expressed PKCβ [19, 21] . Recent studies have shown that in PKCβ " , the C-terminal 642 site also controls Ca# + affinity [22] .
Although priming phosphorylations have been well-characterized in the cPKC isotypes PKCα and PKCβ, little is known of these events in the novel and atypical classes of PKC. In order to investigate priming phosphorylation in the non-conventional PKCs and the specificity of these processes, activation loop mutations were derived for novel and atypical PKCs. Here we show that putative phosphorylation-site mutation in the activation loops of PKCδ, PKCε and PKCζ confer dominant negative properties on these proteins in i o. Furthermore, the results show that these inhibitory properties operate in a heterologous fashion, providing evidence for a common step in the processing of all these PKC isotypes.
MATERIALS AND METHODS

Construction of PKCα, δ, ε and ζ mutant cDNA expression vectors
PKC mutants were constructed using bovine PKCα, rat PKCδ, mouse PKCε and rat PKCζ cDNAs [23] [24] [25] [26] . Exchange of the , ε(T\A) % and ζ(T\A) % ; these sites were utilized during the screening. The mutated sequence was verified by sequence analysis using the Sequenase 2.0 kit (United States Biochemical Corp., Cleveland, OH, U.S.A.). The EcoRI digestion of the pAlter-1 plasmids containing the different PKCδ mutants yielded a 2.8 kbp fragment that was subcloned into pcDNA3 for expression in COS-1 cells. The SphI\KpnI digestion fragment of pAlter-1 containing the PKCε mutants was subcloned in the wrong sense into pSL301. From this vector, a 3.1 kbp KpnI\SalI fragment was subcloned into pcDNA3. PKCζ mutants were digested with SalI\EcoRI from p-Alter-1 and recloned using an EcoRI\XhoI fragment into pcDNA3. The PKCα(T\A) $ mutant was as described previously [15] .
The constitutively active PKCα and ε mutants were expressed using the pMT2 vector. These PKCs are full-length α and ε constructs with a deletion in their inhibitory pseudo-substrate sequences within the regulatory domain. Mutants in the regulatory domain were generated by deletion of amino acids [22] [23] [24] [25] [26] [27] [28] in the pseudo-substrate site (ψSS) of PKCα [27] and 154-163 in PKCε(ψSS) [28] . The PKCα regulatory domain was generated by taking the SacI fragment from pKS-1 PKCα. The 3h-overhang was removed by T4 DNA polymerase and the fragment was cut with EcoRI at the 5h-end, followed by ligation into pcDNA3 restriction-digested with EcoRI\XbaI (blunted). For the α mutant of the catalytic fragment of PKC (PKM ; the PKMα mutant), the BstXI\XhoI fragment of PKCα was subcloned into a BstXI\ XhoI-restriction-digested His ' -tagged PKMα (wild-type) construct (F. Bornancin and P. J. Parker, unpublished work). For the construction of the membrane-targeted CD2-PKM(T\A) $ mutant, the catalytic domain of PKCα(T\A) $ (from bp 972 to the 3h-end) was amplified by PCR using the following oligonucleotide primers : 5h-GCGCTGCGGCCGCAAGCTTGGC-CCTGCCGGCAACA 3h-GTAGGACGTCTCGCGCCATAC-TGAGCTCGATCC. A NotI restriction site was introduced at the 5h-end, for ligation into pcDNA3\BamHI-rCD2\NotI (kindly provided by Doreen Cantrell, ICRF, London) restrictiondigested with NotI and XhoI.
To demonstrate that the newly generated construct CD2-PKM-α(T\A) $ in pcDNA3 encoded the correct PKM fusion protein, the DNA was transiently transfected by electroporation into COS-1 cells. Western blot analysis with rCD2 mAb, Ox34, revealed the presence of the expected approx. 70 kDa species. In parallel with Western blot analysis, cell-surface expression of the CD2-PKCα(T\A) $ chimaera was demonstrated by flow cytometry (or fluorescence-activated cell sorting ; FACS), employing Ox34.
Reporter construct
The TPA (or PMA) response element (TRE)-luciferase reporter plasmid contains three copies of TRE (TGACTCA) upstream of the luciferase structural gene and it was constructed as follows : a ScaI\BglII fragment from PBL-chloramphenicol acetyltransferase (CAT)2 containing the TK promoter was inserted into the luciferase reporter gene PGL-2 plasmid (Promega), where the simian virus 40 (SV40) promoter is downstream of the luciferase structural gene.
Assay for luciferase activity
COS-1 cells were maintained in Dulbecco's modified Eagle's medium with 10 % (v\v) foetal-calf serum, penicillin (100 units\ ml) and streptomycin (100 µg\ml) at 37 mC in 10% CO # in humidified air. One day before transfection, COS-1 cells were plated at a density of 0.3i10& cells per 60-mm culture dish. Calcium phosphate DNA precipitates [29] were prepared with 5 µg of TRE-luciferase, 0.5 µg of the constitutively active mutant and 1 µg of each plasmid expressing an individual PKC-isotype mutant or the control vector pcDNA3 or 5 µg of TRE-luciferase plus 1.5 µg of empty vector. An equal amount of transfection mix was added to two separate plates for each transfected sample. In some experiments, these plates were harvested separately for luciferase assays and for electrophoresis and Western blot analysis. The cells were washed three times with Dulbecco's modified Eagle's medium 12-15 h after transfection, and then fresh culture medium with 2 % (v\v) foetal-calf serum was added to the dishes. The dishes were washed twice with PBS 48 h after transfection. Then 300 µl of lysis buffer [0.65 % Nonidet P40\ 10 mM Tris\HCl (pH 8.0)\1 mM EDTA\150 mM NaCl] was added ; the lysate was transferred to a tube when the intact nuclei were visible under the microscope. After centrifugation, 20 µl of the supernatant was transferred to a polystyrene luminometer cuvette with 350 µl of luciferase reaction buffer [25 mM glycylglycine (pH 8.0)\5 mM ATP (pH 8.0)\15 mM MgSO % ]. Luciferase activity was determined by addition of 33 µl of 3 mM luciferin (Sigma) as described previously [30] . The background measurement was subtracted from each duplicate, and experimental values are expressed as the percentages of the total activity found in extracts from cells transfected with constitutively active mutants. Some of these plates were harvested with 200 µl of Laemmli sample buffer [31] and samples were subjected to SDS\PAGE and Western blot analysis (see text and Figure  legends) .
Western blot analysis
COS-1 cells were transfected as above, except for the data in Figure 3 where 10 % (v\v) foetal-calf serum was employed. After 48 h of transient expression, the cells were washed with ice-cold PBS and lysed in 300 µl of an ice-cold lysis buffer containing 20 mM Tris\HCl, pH 7.5, 10 mM EGTA, 10 mM EDTA, 1 % (v\v) Triton X-100, 2 mM 2-mercaptoethanol, 5 mM benzamidine, 50 µg\ml leupeptin, 50 µg\ml aprotinin, 50 µg\ml trypsin inhibitor, 5 µg\ml pepstatin, 1 mM PMSF, 20 mM NaF, 1 mM Na $ VO % and 1 mM p-nitrophenyl phosphate. This procedure, and all others subsequently, were performed at 4 mC. The suspension was subjected to 50 strokes in a Dounce homogenizer and centrifuged at 12 000 r.p.m. (14 000 g) for 30 min at 4 mC. 100 µl of 4iSDS sample buffer was added to the supernatant (Tritonsoluble extract) and the pellet was resuspended in 400 µl of 1iSDS sample buffer (insoluble fraction). Cell lysates were sonicated, boiled for 3 min, separated on a running gel containing 7.5 % (v\v) acrylamide and 0.06 % (v\v) bisacrylamide, and then subjected to immunoblot assay with polyclonal antibodies specific to each PKC as described previously [24, 26, 32, 33] .
Other methods
Protein concentration was determined by the bicinchoninic acid method (Pierce, Rockford, IL, U.S.A.), with BSA as the standard.
RESULTS
To assess the dominant negative potential of PKC activation loop phosphorylation-site mutants, two of these were tested for their ability to block reporter gene activation by their cognate activated forms, mutated at their inhibitory pseudo-substrate sites [27] . This latter mutation confers ligand-independent activity on the proteins, but does not by-pass any requirement for posttranslational modification. As illustrated in Figure 1 (left panel), activated PKCα co-transfected with a TRE-luciferase construct induced an approx. 10-fold increase in luciferase activity, consistently with previous data [27, 34, 35] . Co-expression of the mutant PKCα(T\A) $ with activated PKCα leads to a complete block in luciferase induction. Thus this mutant PKCα protein has dominant negative properties with respect to PKCα.
In a similar fashion, the effect of two mutant PKCε constructs was tested on the ability of activated PKCε to induce luciferase from a TRE-dependent reporter construct. Unlike wtPKCα, wtPKCε overexpression alone is sufficient to elicit luciferase induction (Figure 1, right panel) . A similar ' basal ' activity of wtPKCε has been noted on transfection of this construct into RAW cells [35] . Expression of the activated PKCε produces a more effective (approx. further 2-fold) increase in luciferase. This induction is inhibited by both the (T\A) " and (T\A) % PKCε mutants (65 % and 75 % inhibition respectively), although their efficacy is less than that observed for the PKCα mutant acting on PKCα.
The above data demonstrate that both the PKCα and PKCε mutants have dominant negative effects on their active counterparts. To determine the specificity of action of these mutants, as well as similar mutant forms of PKCδ and PKCζ, co-transfection experiments were carried out with activated PKCα, a TREluciferase reporter and each of the mutant PKC isotypes (or the appropriate vector control). As illustrated in Figure 2 , all the mutants tested inhibit activated PKCα induction of luciferase. In each case, Western blot analyses were performed to determine (i) the expression of the dominant negative constructs for δ, ε and ζ (Figure 2 , inset) and (ii) the expression of the activated PKCα (lower panel). Although each mutant was expressed, evidently PKCε(T\A) % and PKCζ(T\A) % were poorly expressed compared with their (T\A) " counterparts (there was no consistent difference in the electrophoretic migration of the mutants of an individual isotype). Nevertheless, these (T\A) % mutant constructs proved to be more effective as inhibitors than the (T\A) " mutants. Table 2 presents a summary of the inhibitory effects of these constructs on luciferase induction by activated PKCα and activated PKCε. Over the entire series of experiments, all dominant negative mutants showed a mean inhibition of at least 50 %. However, there are relative differences : thus PKCα(T\A) $ is a more effective inhibitor than PKCζ(T\A) % of activated PKCα, whereas the reverse is true for activated PKCε. Similarly, PKCε(T\A) " is a poorer inhibitor of activated PKCα than PKCδ(T\A) "
, whereas the opposite is true for activated PKCε. The data indicate that these PKC mutants are not specific for the individual isotypes, although they do display relative differences in specificity.
The Western blots of activated PKCα (Figure 2 ) provide evidence that all the mutants modulate PKCα phosphorylation. This is consistent with previous studies on the PKCα(T\A) $ mutant [15] . The active phosphorylated form of PKCα is the 80 kDa species and it is evident from the data shown that all mutants reduce the amount of this form in a manner that approximately corresponds to their ability to inhibit luciferase induction. Thus the weakest inhibitor in this series of experiments [PKCε(T\A) " ] also causes the smallest loss of the 80 kDa PKCα species. These shifts in the 80 kDa species of activated PKCα are consistent with inhibitory effects of the mutant PKC isotypes on phosphorylation. However, owing to the constitutive accumulation of dephosphorylated, activated PKCα, it is impossible to assess increased accumulation of this dephosphorylated form (ligand-activated, open-conformation PKCα has been shown to be a much better substrate for protein phosphatases than the
Figure 2 Inhibition of constitutively active PKCα-induced TRE-luciferase activity by dominant negative mutants of PKCδ, PKCε and PKCζ
COS-1 cells were transfected with a TRE-luciferase reporter construct together with either an empty vector (white) or with the PKCα constitutively active, α* (black) or the PKCα constitutively active together with the different mutants for PKC-δ, -ε and -ζ (dotted). The induced luciferase activity is shown in arbitrary units (au). This is one of seven independent experiments (see summary of data in Table 2 ). The inset is a Western blot showing the expression of the dominant negative mutants. Lower panel : the expression of constitutively active PKCα, where the horizontal bars indicate migration of the 80 kDa and 76 kDa forms of PKCα. The transfections, luciferase activity determination, SDS/PAGE and the Western blots were carried out as described in the Materials and methods section.
Table 2 Inhibition of constitutively active PKCα or PKCε by different PKC dominant negative mutants
The experiments were carried out as indicated in Figure 2 . The data shown are the mean for seven independent transfections, each performed in duplicate. The luciferase activity is expressed as a percentage of the luciferase activity induced by each constitutively active mutant alone after subtraction of the activity induced by the empty vector.
Activated mutants
Dominant
Luciferase activity (% of the control) negative mutants α* ε* inactive protein [11] , consistent with the observed accumulation of the dephosphorylated activated form). In order to determine the effect on dephosphorylation in a more suitable context,
Figure 3 Unphosphorylated PKCα accumulates in response to dominant negative PKC mutants
COS-1 cells co-transfected with either wtPKCα plus empty vector or wtPKCα plus the different mutants were extracted and fractionated into cytosol and Triton-X-100-soluble fraction (S) and Triton-X-100-insoluble (I) fraction (as described in the Materials and methods section). Equivalent samples from each fraction were separated in SDS/PAGE and PKCα was detected by Western blot analysis. Upper and lower horizontal bars indicate the migration of phosphoand dephospho-PKC respectively. This is a representative of 2-4 independent experiments for each PKC isotype.
dominant negative mutants were tested on wtPKCα, which accumulates largely as an 80 kDa species (i.e. fully phosphorylated). To evaluate the effects of the mutants on the phosphorylation state of wtPKCα, co-transfections were carried out as described above for the constitutively activated forms. As shown in Figure 3 , each of the mutants leads to the accumulation of dephosphorylated wtPKCα and a substantial proportion of this dephosphorylated protein is characteristically in the Triton X-100-insoluble fraction. At these ratios of wt : mutant PKC plasmid, the inhibitory effect is incomplete : at higher ratios, the inhibition can be virtually complete (for example, see [15] ) ; the data shown here reflect the concentrations employed with the activated PKC isotypes. For PKCε(T\A) " , longer exposure of the Western blot was required to reveal the insoluble PKCα that accumulated ; this is consistent with the weaker effect of this mutant (see Table 2 ).
The broad specificity of these dominant negative PKC mutants and their action indicates that they might each suppress phosphorylation by a non-productive interaction with a shared binding protein (e.g. a common PKC kinase). However, it is possible that inhibition is exerted through regulatory domain interactions with effectors, in the context of compromised protein kinase activity. To test this, a PKCα regulatory domain construct was co-expressed with wtPKCα. However, this deletion mutant had no effect on PKCα phosphorylation, as judged by its migration at 80 kDa ( Figure 4A ). In order to assess the minimum requirement for inhibition, the kinase domain of PKCα containing the (T\A) $ mutation was also investigated. This construct was found not to inhibit PKCα phosphorylation (Figure 4) . Furthermore, membrane targeting of the PKCα(T\A) $ as a CD2-fusion construct was also found not to inhibit wtPKCα phosphorylation ( Figure 4B ), despite its expression at the membrane as determined by FACS analysis (results not shown). The results indicate that effective competition requires an intact mutant kinase.
DISCUSSION
The results presented here have a number of implications for PKC function and properties. It is established that mutations in the activation loops of PKCδ, ε and ζ have dominant negative properties on expression in COS-1 cells. It is shown also that these dominant negative properties operate in a heterologous fashion, e.g. PKCζ(T\A) % inhibits activated PKCα. These dominant negative mutants act by blocking the accumulation of phosphorylated PKC, as evidenced by studies with PKCα, indicating that there is a common titratable component that promotes the priming phosphorylations of all these PKC isotypes. Furthermore, this competitive interaction is shown to require an intact mutant protein and is not supported by either the regulatory or mutant catalytic domains alone. It is concluded that phosphorylation of the wtPKCs requires appropriate localization and is effected through at least one overlapping step.
Previous studies from this laboratory have defined Thr-497 as a critical site of phosphorylation for PKCα [16] . Similar data have also been reported for PKCβ # [17] . The Thr-497 site resides in the predicted activation loop of PKCα between kinase domains VII and VIII ; the equivalent region is found to be phosphorylated in many other protein kinases [36] . Expression of cPKC isotypes in bacteria has led to the idea that phosphorylation in this region requires some other mammalian protein, the simplest interpretation being the action of a ' PKC-kinase '. The finding that a PKCα mutant modified in the activation loop has dominant properties was consistent with the view of competition with such a saturable ' PKC-kinase '. Here we investigated the behaviour of cPKC, nPKC and aPKC isotypes mutated in this region. Like the original PKCα mutant, it is established that all have dominant negative properties and that this dominance shows no absolute specificity towards particular PKC isotypes. Thus both activated cPKC and nPKC isotypes are functionally inhibited by mutants derived from all three (cPKC, nPKC and aPKC) subclasses. It is concluded that phosphorylation of all these PKC isotypes in their activation loops occurs in i o, accounting for the observed behaviour of the mutants. Evidence derived from the use of sitespecific antisera on PKC isotypes expressed in eukaryotic cells indicates that this is indeed the case (P. J. Parker, unpublished work). Thus although it has been argued that activation loop (Thr-505) phosphorylation of nPKCδ is not required for activity [37] , eukaryotes nevertheless phosphorylate this site.
These results clearly demonstrate that this type of mutant cannot be employed to define PKC isotype specificity in i o. More interestingly, however, this lack of specificity defines a common step in the processing\activation of all these PKC isotypes. The simplest conclusion is that the mutants compete with a PKC kinase ; however, inhibition could be effected at either a prior or parallel step. Studies on PKCα phosphorylation indicate that all these mutants are able to inhibit the normal accumulation of a fully phosphorylated PKCα protein (Thr-497, Thr-638 and Ser-657 sites [14] ), coincidentally with an increased recovery of PKCα in a Triton-X-100-insoluble fraction. This insolubility is characteristic of the accumulated dephosphorylated form, which is derived normally from activation-induced dephosphorylation (discussed in [14] ). It has been observed that there is a distinction between the behaviour of the low concentration of unphosphorylated PKCα primary translation product, which is soluble, and the dephosphorylated protein, which is insoluble. This distinction may reflect the normal operation of a PKCα chaperone that binds to the primary translation product and is needed to maintain conformation, and hence solubility, before the protein's phosphorylation [14] . In light of the observations here, it is plausible that the common saturable step in the processing of all these PKC isotypes is at the level of such a chaperone, i.e. it is this step that is blocked by the action of the dominant negative mutants. It is noteworthy that there are subtle differences in efficacy between these PKC mutants acting on different activated PKC isotypes. Thus although a common kinase and\or chaperone requirement may be involved in the priming phosphorylations, it is possible that this requires not one, but a series, of related proteins that have overlapping specificity but differing affinities for the PKC isotypes. Characterization of these priming events and the identity of the kinase(s) involved will resolve this issue.
Although the possible action of a common PKC kinase or PKC chaperone would account for the dominant negative activity of these PKC mutants, competition for lipid effector should be considered, since there is evidence that some part of these priming phosphorylations may be due to autophosphorylation [8] . In principle, competition for the allosteric activator DAG would block activation-dependent phosphorylation. However, while this might account for the cPKC and nPKC effects, there is much evidence that aPKCζ is not regulated by DAG (see, for example, [26] ). It is therefore very unlikely that competition for DAG accounts for the effects of these proteins. This conclusion is substantiated by the finding that the PKCα regulatory domain does not affect wtPKCα accumulation as a fully phosphorylated form. The observation that a catalytic domain (T\A) $ mutant, soluble or membrane-targeted, also fails to behave as PKCα(T\A) $ indicates that the effective inhibitory properties of these mutants requires an intact protein. This is likely to reflect structural (e.g. the operation of two binding sites) and\or localization constraints on the action of these dominant negative constructs.
Irrespective of the precise competable step in the processing of these PKC isotypes, the evidence here demonstrates that there is an inhibition at the level of the priming phosphorylations. This highlights the requirement for these phosphorylations in the normal operation of PKC. In particular, it is concluded that the conserved threonine within the sequence Thr-Phe-Cys-Gly-Thr present in the activation loops of PKCα, -δ, -ε and -ζ plays an essential role in maintaining the proteins in their fully primed, active (if latent) conformations. The inability to complete the phosphorylation of one of these proteins and produce the active (latent) form is what is responsible for conferring dominant negative properties on the overexpressed mutants.
